Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Johnson & Johnson (J&J) MedTech’s Monarch Quest ...

Johnson & Johnson's nipocalimab earns FDA Fast Track status for Sjögren's disease, speeding development and review for unmet medical needs.

Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult ...

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...

Johnson & Johnson MedTech said Wednesday its Monarch Quest robotic platform received clearance from the Food and Drug ...

Johnson & Johnson MedTech announced today that the FDA cleared its Monarch Quest technology for robotic-assisted bronchoscopy ...

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...